Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial.
In: JAMA Ophthalmology, Jg. 134 (2016-08-01), Heft 8, S. 888-896
academicJournal
Zugriff:
Titel: |
Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial.
|
---|---|
Autor/in / Beteiligte Person: | Ross, Eric L. ; Hutton, David W. ; Stein, Joshua D. ; Bressler, Neil M. ; Jampol, Lee M. ; Glassman, Adam R. ; Diabetic Retinopathy Clinical Research Network |
Zeitschrift: | JAMA Ophthalmology, Jg. 134 (2016-08-01), Heft 8, S. 888-896 |
Veröffentlichung: | 2016 |
Medientyp: | academicJournal |
ISSN: | 2168-6165 (print) |
DOI: | 10.1001/jamaophthalmol.2016.1669 |
Sonstiges: |
|